Non-Canonical, Strongly Selective Protein Disulfide Isomerases as Anticancer Therapeutic Targets

Protein Disulfide Isomerases (PDIs) are emerging targets in anticancer therapy, with several PDI inhibitors demonstrating anticancer efficacy in preclinical models. Research has largely focused on “canonical” PDIs, such as PDIA1, which contain CXXC active site motifs where C represents Cysteine. Can...

詳細記述

書誌詳細

出版年:	Biomolecules
主要な著者:	Mary E. Law, Zaafir M. Dulloo, Brian Hardy, Ania Kelegama, Reagan Clark, Mariana Rivas Montbrun, Gabriella Antmann, Srihith Nooka, Ronald K. Castellano, Brian K. Law
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2025-08-01
主題:	protein disulfide isomerases PDIA1 AGR2 AGR3 ERp44
オンライン･アクセス:	https://www.mdpi.com/2218-273X/15/8/1146